291 related articles for article (PubMed ID: 30629237)
21. Identification of Bile Acids Responsible for Inhibiting the Bile Salt Export Pump, Leading to Bile Acid Accumulation and Cell Toxicity in Rat Hepatocytes.
Oizumi K; Sekine S; Fukagai M; Susukida T; Ito K
J Pharm Sci; 2017 Sep; 106(9):2412-2419. PubMed ID: 28552691
[TBL] [Abstract][Full Text] [Related]
22. Role of glucuronidation for hepatic detoxification and urinary elimination of toxic bile acids during biliary obstruction.
Perreault M; Białek A; Trottier J; Verreault M; Caron P; Milkiewicz P; Barbier O
PLoS One; 2013; 8(11):e80994. PubMed ID: 24244729
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive Evaluation of Bile Acid Homeostasis in Human Hepatocyte Co-Culture in the Presence of Troglitazone, Pioglitazone, and Acetylsalicylic Acid.
Chang JH; Sangaraju D; Liu N; Jaochico A; Plise E
Mol Pharm; 2019 Oct; 16(10):4230-4240. PubMed ID: 31509422
[TBL] [Abstract][Full Text] [Related]
24. Establishment of a Drug-Induced, Bile Acid-Dependent Hepatotoxicity Model Using HepaRG Cells.
Susukida T; Sekine S; Nozaki M; Tokizono M; Oizumi K; Horie T; Ito K
J Pharm Sci; 2016 Apr; 105(4):1550-60. PubMed ID: 26952880
[TBL] [Abstract][Full Text] [Related]
25. The Function of Multidrug Resistance-associated Protein 3 in the Transport of Bile Acids under Normal Physiological and Lithocholic Acid-induced Cholestasis Conditions.
Wang W; Zeng S; Hu M; Liu Z; Gong L
Curr Drug Metab; 2021; 22(5):353-362. PubMed ID: 33461458
[TBL] [Abstract][Full Text] [Related]
26. Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice.
Woolbright BL; Li F; Xie Y; Farhood A; Fickert P; Trauner M; Jaeschke H
Toxicol Lett; 2014 Jul; 228(1):56-66. PubMed ID: 24742700
[TBL] [Abstract][Full Text] [Related]
27. Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic considerations beyond the direct inhibition of the bile salt export pump.
Rodrigues AD; Lai Y; Cvijic ME; Elkin LL; Zvyaga T; Soars MG
Drug Metab Dispos; 2014 Apr; 42(4):566-74. PubMed ID: 24115749
[TBL] [Abstract][Full Text] [Related]
28. Hepatic levels of bile acids in end-stage chronic cholestatic liver disease.
Fischer S; Beuers U; Spengler U; Zwiebel FM; Koebe HG
Clin Chim Acta; 1996 Jul; 251(2):173-86. PubMed ID: 8862472
[TBL] [Abstract][Full Text] [Related]
29. Chlorpromazine-induced perturbations of bile acids and free fatty acids in cholestatic liver injury prevented by the Chinese herbal compound Yin-Chen-Hao-Tang.
Yang Q; Yang F; Tang X; Ding L; Xu Y; Xiong Y; Wang Z; Yang L
BMC Complement Altern Med; 2015 Apr; 15():122. PubMed ID: 25887351
[TBL] [Abstract][Full Text] [Related]
30. Oleanolic acid alters bile acid metabolism and produces cholestatic liver injury in mice.
Liu J; Lu YF; Zhang Y; Wu KC; Fan F; Klaassen CD
Toxicol Appl Pharmacol; 2013 Nov; 272(3):816-24. PubMed ID: 23948738
[TBL] [Abstract][Full Text] [Related]
31. Hepatocyte-based in vitro model for assessment of drug-induced cholestasis.
Chatterjee S; Richert L; Augustijns P; Annaert P
Toxicol Appl Pharmacol; 2014 Jan; 274(1):124-36. PubMed ID: 24211272
[TBL] [Abstract][Full Text] [Related]
32. Rat precision-cut liver slices predict drug-induced cholestatic injury.
Starokozhko V; Greupink R; van de Broek P; Soliman N; Ghimire S; de Graaf IAM; Groothuis GMM
Arch Toxicol; 2017 Oct; 91(10):3403-3413. PubMed ID: 28391356
[TBL] [Abstract][Full Text] [Related]
33. Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability.
Hendriks DF; Fredriksson Puigvert L; Messner S; Mortiz W; Ingelman-Sundberg M
Sci Rep; 2016 Oct; 6():35434. PubMed ID: 27759057
[TBL] [Abstract][Full Text] [Related]
34. Suppression of autophagic flux by bile acids in hepatocytes.
Manley S; Ni HM; Kong B; Apte U; Guo G; Ding WX
Toxicol Sci; 2014 Feb; 137(2):478-90. PubMed ID: 24189133
[TBL] [Abstract][Full Text] [Related]
35. Protective effects of yangonin from an edible botanical Kava against lithocholic acid-induced cholestasis and hepatotoxicity.
Kong Y; Gao X; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Sun P; Meng Q
Eur J Pharmacol; 2018 Apr; 824():64-71. PubMed ID: 29427579
[TBL] [Abstract][Full Text] [Related]
36. Bile-acid-induced cell injury and protection.
Perez MJ; Briz O
World J Gastroenterol; 2009 Apr; 15(14):1677-89. PubMed ID: 19360911
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of the 3-sulfates of N-acetylcysteine conjugated bile acids (BA-NACs) and their transient formation from BA-NACs and subsequent hydrolysis by a rat liver cytosolic fraction as shown by liquid chromatography/electrospray ionization-mass spectrometry.
Mitamura K; Sakai T; Nakai R; Wakamiya T; Iida T; Hofmann AF; Ikegawa S
Anal Bioanal Chem; 2011 Jun; 400(7):2061-72. PubMed ID: 21455648
[TBL] [Abstract][Full Text] [Related]
38. Hepatic bile acid synthesis and secretion: Comparison of in vitro methods.
de Bruijn VMP; Wang Z; Bakker W; Zheng W; Spee B; Bouwmeester H
Toxicol Lett; 2022 Jul; 365():46-60. PubMed ID: 35724847
[TBL] [Abstract][Full Text] [Related]
39. Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs.
Sharanek A; Burban A; Burbank M; Le Guevel R; Li R; Guillouzo A; Guguen-Guillouzo C
Sci Rep; 2016 May; 6():24709. PubMed ID: 27169750
[TBL] [Abstract][Full Text] [Related]
40. Promising toxicological biomarkers for the diagnosis of liver injury types: Bile acid metabolic profiles and oxidative stress marker as screening tools in drug development.
Masubuchi N; Nishiya T; Imaoka M; Mizumaki K; Okazaki O
Chem Biol Interact; 2016 Aug; 255():74-82. PubMed ID: 26365562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
